Skip to main content
SpringerLink
Log in

Establishment of novel patient-derived models of dermatofibrosarcoma protuberans: two cell lines, NCC-DFSP1-C1 and NCC-DFSP2-C1

  • Published:
In Vitro Cellular & Developmental Biology - Animal Aims and scope Submit manuscript

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a common type of dermal sarcoma, characterized by the presence of the unique collagen type I alpha 1 chain (COL1A1)-PDGFB translocation, which causes constitutive activation of the platelet-derived growth factor β (PDGFB) signaling pathway. Patients with DFSP exhibit frequent local recurrence, and novel therapeutic approaches are required to achieve better clinical outcomes. Patient-derived cancer cell lines are essential in the preclinical research. Here, we established novel patient-derived DFSP cell lines from two patients with DFSP and designated these cell lines NCC-DFSP1-C1 and NCC-DFSP2-C1. Tumors of the two patients with DFSP had COL1A1-PDGFB translocations with distinct COL1A1 breakpoints, e.g., in exons 33 and 15, and the translocations were preserved in the established cell lines. NCC-DFSP1-C1 and NCC-DFSP2-C1 cells exhibited similar morphology and limited capability of proliferation in vitro, forming spheroids when seeded on low-attachment tissue culture plates. In contrast, NCC-DFSP1-C1 cells had considerably higher invasive capability than NCC-DFSP2-C1 cells. Overall proteome contents were similar between NCC-DFSP1-C1 and NCC-DFSP2-C1 cells. Notably, in vitro screening studies identified anticancer drugs that showed antiproliferative effects at considerably low concentrations in the DFSP cell lines. Bortezomib, mitoxantrone, ponatinib, and romidepsin were more cytotoxic to NCC-DFSP1-C1 cells than to NCC-DFSP2-C1 cells. These cell lines will be useful tools for developing novel therapeutic strategies to treat DFSP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.

Similar content being viewed by others

References

  • Baehrecke EH, Dang N, Babaria K, Shneiderman B (2004) Visualization and analysis of microarray and gene ontology data with treemaps. BMC Bioinformatics 5(84):84

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, Brennan MF, Lewis JJ (2000) Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 88:2711–2720

    Article  CAS  PubMed  Google Scholar 

  • Capes-Davis A, Dirks W, MacLeod R, Uphoff C (2014) Quality matters: cell lines and their use in research. GIT Lab J Eur 17:12–13

    Google Scholar 

  • Chang CK, Jacobs IA, Salti GI (2004) Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 30:341–345

    Article  CAS  PubMed  Google Scholar 

  • Corey RM, Swett K, Ward WG (2014) Epidemiology and survivorship of soft tissue sarcomas in adults: a national cancer database report. Cancer Med 3:1404–1415

    Article  PubMed  PubMed Central  Google Scholar 

  • Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367:2075–2088

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Criscione VD, Weinstock MA (2007) Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 56:968–973

    Article  PubMed  Google Scholar 

  • Fields RC, Hameed M, Qin LX, Moraco N, Jia X, Maki RG, Singer S, Brennan MF (2011) Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol 18:328–336

    Article  PubMed  Google Scholar 

  • Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, Casali PG, Gronchi A (2005) Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate. J Clin Oncol 23:7669–7675

    Article  PubMed  Google Scholar 

  • Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F (2013) WHO classification of tumours of soft tissue and bone, Fourth Edition edn. WHO Press, Geneva

    Google Scholar 

  • Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, Wardwell S, Ning Y, Song Y, Kohlmann A, Wang F, Clackson T, Heinrich MC, Fletcher JA, Bauer S, Rivera VM (2014) Ponatinib inhibits polyclonal drugresistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res 20:5745–5755

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gershwin ME, Lentz D, Owens RB (1984) Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice. Exp Cell Biol 52:361–370

    CAS  PubMed  Google Scholar 

  • Gloster HM Jr (1996) Dermatofibrosarcoma protuberans. J Am Acad Dermatol 35:355–374 quiz 375-356

    Article  PubMed  Google Scholar 

  • Greco A, Fusetti L, Villa R, Sozzi G, Minoletti F, Mauri P, Pierotti MA (1998) Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans. Oncogene 17:1313–1319

    Article  CAS  PubMed  Google Scholar 

  • Greco A, Roccato E, Miranda C, Cleris L, Formelli F, Pierotti MA (2001) Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement. Int J Cancer 92:354–360

    Article  CAS  PubMed  Google Scholar 

  • Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG (2008) Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 14:2717–2725

    Article  CAS  Google Scholar 

  • Kamar FG, Kairouz VF, Sabri AN (2013) Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report. Clin Sarcoma Res 3(5)

  • Kerob D, Porcher R, Verola O, Dalle S, Maubec E, Aubin F, D'Incan M, Bodokh I, Boulinguez S, Madelaine-Chambrin I, Mathieu-Boue A, Servant JM, de Kerviler E, Janin A, Calvo F, Pedeutour F, Lebbe C (2010) Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 16:3288–3295

    Article  CAS  PubMed  Google Scholar 

  • Kondo T, Hirohashi S (2007) Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc 1:2940–2956

    Article  CAS  Google Scholar 

  • Lal P, Sharma R, Mohan H, Sekhon MS (1999) Dermatofibrosarcoma protuberans metastasizing to lymph nodes: a case report and review of literature. J Surg Oncol 72:178–180

    Article  CAS  PubMed  Google Scholar 

  • Laskin WB (1992) Dermatofibrosarcoma protuberans. CA Cancer J Clin 42:116–125

    Article  CAS  PubMed  Google Scholar 

  • Llombart B, Sanmartin O, Lopez-Guerrero JA, Monteagudo C, Serra C, Requena C, Poveda A, Vistos JL, Almenar S, Llombart-Bosch A, Guillen C (2009) Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications. Histopathology 54:860–872

    Article  PubMed  Google Scholar 

  • Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR (2002) Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100:623–626

    Article  CAS  PubMed  Google Scholar 

  • Manganoni AM, Pavoni L, Gualdi G, Marocolo D, Chiudinelli M, Sereni E, Farisoglio C, Calzavara-Pinton P (2013) Dermatofibrosarcoma protuberans in an adolescent: a case report and review of the literature. J Pediatr Hematol Oncol 35:383–387

    Article  PubMed  Google Scholar 

  • McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA (2005) Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23:866–873

    Article  CAS  PubMed  Google Scholar 

  • O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401–412

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Oyama R, Takahashi M, Yoshida A, Sakumoto M, Takai Y, Kito F, Shiozawa K, Qiao Z, Arai Y, Shibata T, Araki Y, Endo M, Kawai A, Kondo T (2017) Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines. Sci Rep 7:4712

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD (2002) Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20:3586–3591

    Article  CAS  PubMed  Google Scholar 

  • Rutkowski P, Debiec-Rychter M, Nowecki Z, Michej W, Symonides M, Ptaszynski K, Ruka W (2011) Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol: JEADV 25:264–270

  • Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM (2010) Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 28:1772–1779

  • Shimizu A, O'Brien KP, Sjoblom T, Pietras K, Buchdunger E, Collins VP, Heldin CH, Dumanski JP, Ostman A (1999) The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 59:3719–3723

    CAS  PubMed  Google Scholar 

  • Shindo Y, Akiyama J, Yamaji K, Ishihara Y, Saida T, Takase Y (1989) Establishment of a human dermatofibrosarcoma protuberans cell line: cytological characteristics. J Dermatol 16:355–360

    Article  CAS  PubMed  Google Scholar 

  • Simon MP, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre JM, Terrier-Lacombe MJ, Mandahl N, Craver RD, Blin N, Sozzi G, Turc Carel C, O'Brien KP, Kedra D, Fransson I, Guilbaud C, Dumanski JP (1997) Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet 95–98(535):15

    Google Scholar 

  • Sjoblom T, Shimizu A, O'Brien KP, Pietras K, Dal Cin P, Buchdunger E, Dumanski JP, Ostman A, Heldin CH (2001) Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis. Cancer Res 61:5778–5783

    CAS  PubMed  Google Scholar 

  • Solly K, Wang X, Xu X, Strulovici B, Zheng W (2004) Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2:363–372

    Article  CAS  PubMed  Google Scholar 

  • Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, Gronchi A, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG (2016) Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP). Clin Cancer Res 22:837–846

    Article  CAS  Google Scholar 

  • Takahira T, Oda Y, Tamiya S, Higaki K, Yamamoto H, Kobayashi C, Izumi T, Tateishi N, Iwamoto Y, Tsuneyoshi M (2007) Detection of COL1A1-PDGFB fusion transcripts and PDGFB/PDGFRB mRNA expression in dermatofibrosarcoma protuberans. Mod Pathol 20:668–675

    Article  CAS  PubMed  Google Scholar 

  • Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pfohler C, Schiller M, Hauschild A, Hein R, Kampgen E, Kellner I, Leverkus M, Becker JC, Strobel P, Schadendorf D (2014) Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clin Cancer Res 20:499–510

    Article  CAS  PubMed  Google Scholar 

  • Wisniewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6:359–362

    Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank Drs. Y. Minami, K. Shimizu, T. Uehara, and M. Sugawara, T. Mori, as well as Ms. R. Nakano (Division of Musculoskeletal Oncology, National Cancer Center Hospital) for providing the tumor tissue specimens from surgically resected materials. This study was supported by the National Cancer Center Research and Development Fund (grant number 29-A-2). We would also like to thank Editage (www.editage.jp) for English language editing and constructive comments on the manuscript.

Author information

Authors and Affiliations

  1. Department of Innovative Seeds Evaluation, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Rieko Oyama, Fusako Kito, Marimu Sakumoto & Tadashi Kondo

  2. Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Zhiwei Qiao, Kumiko Shiozawa & Tadashi Kondo

  3. Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Shunichi Toki & Akira Kawai

  4. Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Akihiko Yoshida

Authors
  1. Rieko Oyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fusako Kito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhiwei Qiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marimu Sakumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kumiko Shiozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shunichi Toki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akihiko Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akira Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tadashi Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadashi Kondo.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Additional information

Editor: Tetsuji Okamoto

Electronic supplementary material

ESM 1

(DOCX 14 kb)

ESM 2

(XLSX 29 kb)

ESM 3

(XLSX 5040 kb)

ESM 4

(XLSX 6055 kb)

ESM 5

(XLSX 4432 kb)

ESM 6

(XLSX 5220 kb)

ESM 7

(XLSX 13 kb)

ESM 8

(XLSX 14 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oyama, R., Kito, F., Qiao, Z. et al. Establishment of novel patient-derived models of dermatofibrosarcoma protuberans: two cell lines, NCC-DFSP1-C1 and NCC-DFSP2-C1. In Vitro Cell.Dev.Biol.-Animal 55, 62–73 (2019). https://doi.org/10.1007/s11626-018-0305-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11626-018-0305-z

Keywords

Search

Navigation